Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review

Frontiers in Pharmacology

Pharmacology

A. Quesada-Simó¹  S. Gil-Perotín²  P. Nos³  A. Garrido-Marín³ 

[1] Department of Neurology, Hospital Universitario Dr. Peset, Valencia, Spain;Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain;Gastroenterology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain;

关键词: ocrelizumab;    rituximab;    ulcerative colitis;    crohn’s disease;    microscopic colitis;    anti-S1P;   

DOI  :  10.3389/fphar.2023.1186016

 received in 2023-03-14, accepted in 2023-05-05,  发布年份 2023

来源: Frontiers

【 摘 要 】

Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are autoimmune disorders characterized by inflammatory episodes affecting the brain and the gastrointestinal (GI) tract, respectively. The frequent association between MS and IBD suggests that both conditions may share common pathogenic mechanisms. However, different responses to biological therapies indicate differences in immune mechanisms of inflammation. Anti-CD20 therapies are high efficacy treatments increasingly used to control inflammatory bursts in MS, but they may alter GI homeostasis and promote the development of bowel inflammation in susceptible individuals. This review analyzes the mechanistic association between immunity in MS and IBD, the effect of anti-CD20 therapies on the gut microenvironment, and provides recommendations for early detection and management of GI toxicities in the context of B-cell depletion in MS patients.

【 授权许可】

Unknown   
Copyright © 2023 Quesada-Simó, Garrido-Marín, Nos and Gil-Perotín.